1219741-79-3

Basic information

• Product Name: 4-bromo-5-fluoro-2-iodo-phenylamine
• Synonyms: 4-bromo-5-fluoro-2-iodo-phenylamine;4-Bromo-5-fluoro-2-iodoaniline
• CAS NO: 1219741-79-3
• Molecular Formula: C₆H₄BrFIN
• Molecular Weight: 315.9095332
• Mol File: 1219741-79-3.mol

Chemical Properties

• Boiling Point: 289.2±40.0 °C(Predicted)
• Appearance: /
• Density: 2.354±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.82±0.10(Predicted)
• CAS DataBase Reference: 4-bromo-5-fluoro-2-iodo-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-5-fluoro-2-iodo-phenylamine(1219741-79-3)
• EPA Substance Registry System: 4-bromo-5-fluoro-2-iodo-phenylamine(1219741-79-3)

Safety Data

• Hazardous Substances Data: 1219741-79-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-5-fluoro-2-iodo-phenylamine is used as a building block for the development of new drugs due to its unique structure and reactivity. It plays a crucial role in the synthesis of biologically active molecules, contributing to the advancement of medicinal chemistry.
Used in Organic Synthesis:
In the realm of organic synthesis, 4-bromo-5-fluoro-2-iodo-phenylamine is utilized as a versatile intermediate for creating a variety of complex organic compounds. Its distinct properties allow for multiple synthetic pathways, making it a valuable component in the construction of diverse chemical libraries.
Used in Materials Science:
4-bromo-5-fluoro-2-iodo-phenylamine may have potential applications in materials science, where its unique structure could contribute to the development of new materials with specific properties. Its halogens may influence the material's characteristics, such as stability, reactivity, or electronic properties.
Used in Agrochemicals:
Additionally, 4-bromo-5-fluoro-2-iodo-phenylamine could be employed in the agrochemical industry, where its chemical properties might be harnessed for the development of new pesticides or other agricultural chemicals. Its potential use in this field highlights its versatility across different scientific and industrial applications.

Upstream product

• 656-65-5 3-fluoro-4-bromophenylamine 
• 351-28-0 N-(3-fluorophenyl)acetamide 
• 351-30-4 N-(4-bromo-3-fluorophenyl)ethanamide 
• 372-19-0 meta-fluoroaniline 

Downstream Products

• 1219741-80-6 4-bromo-5-fluoro-2-[(trimethylsilyl)ethynyl]aniline 
• 1427358-21-1 6-fluoro-1H-indole-5-carbonitrile 
• 434960-42-6 5-bromo-6-fluoro-1H-indole 

Relevant articles and documents

CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS

The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Bicyclic sulfonamide compounds as sodium channel inhibitors

The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

TRICYCLIC SULFONAMIDE DERIVATIVES

The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of pain.

TRICYCLIC SULFONAMIDE DERIVATIVES

The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of pain.

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Positive allosteric modulators of nicotinic acetylcholine receptor

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS

The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula (I), pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metabolic disorders and complications thereof, as well as methods for the treatment of the metabolic disorders and complications thereof.

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.